Navigation Links
ISTA Pharmaceuticals Achieves 2010 Revenue and Earnings Guidance; Provides 2011 Financial Guidance and Updates Key Plans
Date:1/5/2011

IRVINE, Calif., Jan. 5, 2011 /PRNewswire/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), announced today, during its previously announced guidance call, that it expects to achieve its 2010 net revenues guidance of $147 million to $167 million with anticipated, unaudited net revenues in the mid-$150 million range.  The company also said it expects to exceed $1 million in unaudited net income in 2010, before any warrant expense.

President and Chief Executive Officer Vicente Anido, Jr., Ph.D., said, "ISTA has established itself as a successful pharmaceutical developer, an aggressive competitor and a fast-growing, profitable specialty pharmaceutical company. We've managed effectively through the company's start-up phase, obtained FDA approval to market five drugs in just six years, and established a formidable sales force calling on ophthalmologists, optometrists and allergists.  In 2010, we achieved revenue growth of about 40% as compared to 2009, while delivering our first year of profitability."

2011 Financial Outlook in Detail

On today's guidance call, Chief Financial Officer and Vice President of Corporate Development Lauren Silvernail reiterated the company's 2011 revenues guidance provided on the third quarter 2010 earnings call and gave additional detail on revenue, expenses, income and cash.  ISTA expects:  

  • 2011 net revenues will be approximately $175 million to $190 million.
  • 2011 gross margins will be in the 75% to 77% range.
  • 2011 R&D expenses will be 18% to 22% of net revenues.
  • 2011 SG&A expenses will be 44% to 48% of net revenues.
  • 2011 operating income will be $13 million to $16 million.
  • 2011 net income will be $5 million to $8 million, or fully diluted earnings per share of $0.11 to $0.18, assuming 44 million fully diluted shares and
    '/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014  ConvaTec, a privately-held medical products and ... has been appointed chief financial officer of the company, ... previously executive vice president and chief financial officer of ... company.  Mr. Clerkin was part of a senior team ... in its sale to Perrigo, a pharmaceutical manufacturer, in ...
(Date:7/22/2014)... LOUIS , July 22, 2014  According to ... time their children spend on digital devices. An AOA ... ages of 10 and 17 estimate they use an ... However, a separate AOA survey of parents revealed that ... an electronic device for that same amount of time. ...
(Date:7/22/2014)... LOS ANGELES , July 22, 2014  NeuroSigma, ... sciences company focused on commercialization of its non-invasive ... of neurological and neuropsychiatric disorders, today announced that enrollment ... external trigeminal nerve stimulation (eTNS) as adjunctive therapy for ... trial is being conducted at the Olive View-UCLA Medical ...
Breaking Medicine Technology:ConvaTec Names Nigel Clerkin Chief Financial Officer 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 3Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5
(Date:7/22/2014)... Antonio, TX (PRWEB) July 22, 2014 Dr. ... Designed with existing patients and new visitors in mind, one ... clean, modern and visual layout that makes navigation very easy. ... make the experience of going to the dentist affordable, convenient ... , One helpful new feature is an appointment scheduling system ...
(Date:7/22/2014)... Indianapolis, IN (PRWEB) July 22, 2014 ... benefits advisory organization, announces that Les McPhearson, an insurance ... serve as CEO effective immediately and be based in ... Calise, said, "I am delighted that Les chose to ... is perfectly qualified to address the many challenges facing ...
(Date:7/22/2014)... HealthDay Reporter TUESDAY, July 22, 2014 (HealthDay ... in the veins of the legs appear no different in ... risk of bleeding and average hospitalization bills that are three ... finds. The standard treatment for these clots -- known ... compression stockings. The other, more expensive treatment delivers medication directly ...
(Date:7/22/2014)... 22, 2014) The American Society of Hematology (ASH) ... School of Medicine, and Robert P. Hebbel, MD, of ... Ernest Beutler Lecture and Prize for their significant research ... The Ernest Beutler Lecture, named for the late Ernest ... for more than 50 years, is a two-part lectureship ...
(Date:7/22/2014)... research at the University of Utah,s John A. Moran ... of Eye Research (ISER) as the recipient of the ... Award in Retina Research., The award recognizes lifetime achievement ... contribution to the understanding of vitreoretinal diseases or disorders. ... ISER Biennial Meeting in San Francisco, where Marc will ...
Breaking Medicine News(10 mins):Health News:Dr. Dental Reveals Exciting New Website 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 3Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 4Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 5Health News:Study Casts Doubt on Costly Treatment for Leg Clots 2Health News:Study Casts Doubt on Costly Treatment for Leg Clots 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 2Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 4Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2
... Rostock Center for the study of Demographic Change, have ... be //soon reduced, if the trend of low participation ... ,The Rostock Center is a research institution, ... for Demographic Research and the University of Rostock. The ...
... lead in a global ,program to catalogue human mutations in ... access//. ,For a sample of the expected ... professor at the division of human genetics at the University ... a family who suffered from a heredity eye disease, which ...
... A Geography professor of Kansas State University, Doug Goodin, ... of land use and land cover //changes on human ... uses, combines remote sensing with other types of data, ... Along with other scientists he recently discussed this subject ...
... Chicago – The extended use of anabolic androgenic steroid ... // Gingival enlargement occurs when the tissues ... is a fertile environment for bacteria to grow, which ... that AAS abusers had statistically significant levels of gingival ...
... of misconception about Cannabis and its effects. It is widely ... // Such misrepresentations of the drug have resulted in making ... Karolinska Institute in Sweden have unearthed the harmful effects of ... ingredient in cannabis. It was found that the brain of ...
... medical specialist, NHS can be freed from its’ problems, ... before they are implemented. // It is amply clear ... make matters worse for the deprived and under privileged ... led to low morale among Doctors and NHS staff. ...
Cached Medicine News:Health News:Demographic Change Demand a New Life-Course for Aging Society 2Health News:Developing Countries Undertake Cataloguing of Human Mutations 2Health News:Developing Countries Undertake Cataloguing of Human Mutations 3Health News:Satellite Imagery to monitor the Social Impact Of Geographical Changes 2Health News:A connection between gingival enlargement and steroid abuse 2
Landolt hypophysectomie instrument, spoon, bayonet-shaped, flexible....
Hardy pituitary spoon, bayonet, malleable....
... Sundt AVM Micro ... construction, non-magnetic, MRI compatible, ... coiled, high minimum closing ... of small perforating vessels ...
... Cougar is an Anterior Spinal Implant system. ... approximating that of cortical bone. The result ... requirements of anterior column support, while optimizing ... sharing design. Incorporates an anatomic design with ...
Medicine Products: